Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves’ ophthalmopathy-Reference-Cited by-同舟云学术

Overall safety and efficacy of high-dose and low-dose intravenous glucocorticoid therapy in patients with moderate-to-severe active Graves’ ophthalmopathy

Published:2016 Issue:8 Volume:63 Page:703-714
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Ueda-Sakane Yoriko¹,Kanamoto Naotetsu¹²,Fushimi Yasutaka³,Tanaka-Mizuno Sachiko⁴⁵,Yasuno Shinji⁴,Miura Masako¹⁶,Sone Masakatsu¹,Yasoda Akihiro¹,Okada Tomohisa³,Togashi Kaori³,Nakao Kazuwa⁷,Inagaki Nobuya¹

Affiliation:

1. Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan

2. Department of Endocrinology, Osaka City General Hospital, Osaka 534-0021, Japan

3. Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan

4. Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital, Kyoto 606-8507, Japan

5. Department of Biostatistics, Shiga University of Medical Science, Otsu 520-2192, Japan

6. Department of Endocrinology, Rakuwakai Otowa Hospital, Kyoto 607-8062, Japan

7. Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto 606-8501, Japan

Publisher

Japan Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.jstage.jst.go.jp/article/endocrj/63/8/63_EJ16-0038/_pdf

Reference25 articles.

1. 1. Burch HB, Wartofsky L (1993) Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 14: 747-793.

2. 2. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, et al. (2009) Treatment modalities for Graves’ ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab 94: 2708-2716.

3. 3. Weissel M, Hauff W (2000) Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 10: 521.

4. 4. Marino M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, et al. (2004) Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid 14: 403-406.

5. 5. Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP, et al. (2007) Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves’ ophthalmopathy. Thyroid 17: 357-362.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of Different Treatment Modalities in Initial and Chronic Phases of Thyroid Eye Disease: A Systematic Review With Meta-analysis;The Journal of Clinical Endocrinology & Metabolism;2024-07-30

3. Efficacy and Safety of Different Intravenous Glucocorticoid Regimens in the Treatment of Graves’ Ophthalmopathy: A Meta-Analysis;Journal of Ophthalmology;2021-07-12

4. Severe Graves' disease‐associated orbitopathy: A rare case of frontal bone hemangioma;Clinical Case Reports;2020-12-10

5. Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application;Therapeutic Advances in Endocrinology and Metabolism;2020-01